Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI
Not yet recruiting · NCT07819214 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Epcoritamab as Consolidation Therapy for High-Risk Pts w/CLL on BTKI | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Not yet recruiting | Phase 2 | 2026-09-14 | NCT07819214 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Genmab | 54 |
| University of California, Irvine | 157 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chao Family Comprehensive Cancer Center, University of California, Irvine | Orange | United States | 24 |